logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9326973 B1

PDFFull Text
Date of Patent:
May. 03, 2016

Filed:

Jan. 07, 2013

Hepatitis c virus inhibitors

Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Piyasena Hewawasam, Middletown, CT (US);

John F. Kadow, Wallingford, CT (US);

Omar D. Lopez, Wallingford, CT (US);

Nicholas A. Meanwell, East Hampton, CT (US);

Yong Tu, Cheshire, CT (US);

Alan Xiangdong Wang, Wallingford, CT (US);

Ningning Xu, Wallingford, CT (US);

Samayamunthula Venkata Satya Arun Kumar Gupta, Bangalore, IN;

Pothukanuri Srinivasu, Bangalore, IN;

Indasi Gopi Kumar, Bangalore, IN;

Ponugupati Suresh Kumar, Bangalore, IN;

Makonen Belema, North Haven, CT (US);

Robert A. Fridell, Guilford, CT (US);

Min Gao, Madison, CT (US);

Julie A. Lemm, Durham, CT (US);

Donald R. O'Boyle, II, Killingworth, CT (US);

Jin-Hua Sun, North Haven, CT (US);

Chunfu Wang, Cheshire, CT (US);

Ying-Kai Wang, Rocky Hill, CT (US);

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:

Pamela A. Mingo

Primary Examiner:

Shengjun Wang

Int. Cl.
CPC ...
A61K 31/415 (2006.01); A61K 31/675 (2006.01); A61K 38/00 (2006.01); A61K 31/4178 (2006.01); A61K 31/407 (2006.01); A61K 31/4184 (2006.01); A61K 31/422 (2006.01); A61K 31/423 (2006.01); A61K 31/428 (2006.01); A61K 31/437 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/498 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/55 (2006.01); A61K 31/7056 (2006.01); A61K 38/05 (2006.01); A61K 38/21 (2006.01); A61K 45/06 (2006.01); C07D 403/14 (2006.01); C07D 491/113 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4178 (2013.01); A61K 31/407 (2013.01); A61K 31/4184 (2013.01); A61K 31/422 (2013.01); A61K 31/423 (2013.01); A61K 31/428 (2013.01); A61K 31/437 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 31/7056 (2013.01); A61K 38/05 (2013.01); A61K 38/21 (2013.01); A61K 38/212 (2013.01); A61K 38/217 (2013.01); A61K 45/06 (2013.01); C07D 403/14 (2013.01); C07D 491/113 (2013.01);
Abstract

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Find Patent Forward Citations

Loading…